Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : J&J Recalls Nearly 54,000 Packages Of Imodium Antidiarrhea Medicine

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/17/2012 | 07:41pm CEST
   By Peter Loftus 
   Of  
 

Johnson & Johnson (JNJ) has recalled nearly 54,000 packages of Imodium Multi-Symptom Relief antidiarrhea pills due to a potential packaging defect.

J&J's McNeil consumer-health division said Thursday an internal review revealed the potential for a limited number of blister-packaging units--which contain the pills--to have dents with a small pinhole or tear.

J&J said the voluntary recall was being conducted at the wholesale level only, and not from consumers or store shelves. J&J said there were no safety concerns or adverse events associated with the recall.

The company said consumers may continue to use the product if there is no hole or tear in the blister unit. An Imodium caplet taken from a damaged blister unit, however, may not provide the full benefit of the product as intended. J&J advised patients not to take the product if the blister unit is torn or open.

J&J said it has made improvements to the packaging line to try to prevent the issue from happening again.

J&J has manufactured more than 2.75 million packages of Imodium Multi-Symptom Relief Caplets over the past five months, and except for the one lot being recalled, the product remains on store shelves, said spokeswoman Barbara Montresor.

J&J's McNeil unit has issued a series of recalls for popular over-the-counter medicines like Tylenol over the past two and a half years for various quality lapses. The recalls have cost the company hundreds of millions of dollars in lost sales and costs to fix the manufacturing problems.

More information about the recall can be found at the Imodium product website: http://www.imodium.com/page.jhtml?id=imodium/include/news.inc.

J&J shares rose 0.2% to $63.81 in recent trading.

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; peter.loftus@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
08/21 JOHNSON & JOHNSON : Hit With Record Talc-Ovarian Cancer Verdict of $417 Million
08/21 SEMPRA ENERGY : Business Highlights
08/21 THE LATEST : Plaintiff wanted to help others in talc case
08/21DJJOHNSON & JOHNSON : Hit With $417 Million Verdict in Baby Powder Case
08/21 JOHNSON & JOHNSON : Record $417M award in lawsuit linking baby powder to cancer
08/21 JOHNSON & JOHNSON : J&J hit with $417m bill in talc cancer claim
08/21 JOHNSON & JOHNSON : New XARELTO® (rivaroxaban) Data at ESC Congress 2017 Include..
08/21DJJOHNSON & JOHNSON : Wades Into Death Penalty Debate For First Time
08/20 BAYER : Xarelto Lawsuit Decision Goes in Favor of Bayer, Johnson & Johnson
08/17 JOHNSON & JOHNSON : Ethicon Transvaginal Mesh Lawsuits Move Forward in Pennsylva..
More news
News from SeekingAlpha
08/21 Cash Flow At L Brands Is Still The Answer Going Forward, With 6.6% Yield
08/21 J & J on the hook for $417M in California talcum powder case
08/21 Seeking Confirmations - U.S. Stock Market
08/21 THE IM-CAPITAL STRENGTH 20-STOCK UNI : Aug-2017 Update
08/21 JOHNSON & JOHNSON : Bring On The Ambulance Chasers
Financials ($)
Sales 2017 75 842 M
EBIT 2017 22 815 M
Net income 2017 16 213 M
Debt 2017 17 708 M
Yield 2017 2,53%
P/E ratio 2017 22,08
P/E ratio 2018 17,96
EV / Sales 2017 4,93x
EV / Sales 2018 4,46x
Capitalization 355 979 M
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 21
Average target price 136 $
Spread / Average Target 2,8%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON15.12%355 979
NOVARTIS7.69%216 915
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554
MERCK AND COMPANY4.45%167 705
SANOFI6.97%122 127